Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Early Phase 1

17(73.9%)

Phase 1

4(17.4%)

N/A

2(8.7%)

23Total

Early Phase 1(17)

Phase 1(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT06548607Early Phase 1Recruiting

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

Role: lead

NCT07441525Early Phase 1Recruiting

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

Role: collaborator

NCT06549296Early Phase 1Suspended

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

Role: lead

NCT05895994Early Phase 1Completed

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

Role: collaborator

NCT06548620Early Phase 1Withdrawn

A Study of RD06-04 in Patients With Active Autoimmune Diseases

Role: lead

NCT06775912Early Phase 1Recruiting

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Role: lead

NCT07337785Early Phase 1Recruiting

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Role: collaborator

NCT07203404Early Phase 1Recruiting

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

Role: lead

NCT07142161Early Phase 1Active Not Recruiting

A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM

Role: lead

NCT06622694Phase 1Recruiting

CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia

Role: collaborator

NCT04689204Early Phase 1Completed

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Role: collaborator

NCT06732492Phase 1Recruiting

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

Role: collaborator

NCT05923541Early Phase 1Completed

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Role: collaborator

NCT05907603Early Phase 1Completed

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Role: collaborator

NCT05716113Early Phase 1Completed

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Role: collaborator

NCT05902845Early Phase 1Completed

RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

Role: collaborator

NCT05015972Early Phase 1Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

Role: collaborator

NCT04227015Early Phase 1Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy